<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03997305</url>
  </required_header>
  <id_info>
    <org_study_id>1890</org_study_id>
    <nct_id>NCT03997305</nct_id>
  </id_info>
  <brief_title>AltaValve Early Feasibility Study Protocol</brief_title>
  <official_title>AltaValve Early Feasibility Study Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>4C Medical Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>4C Medical Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, single-arm, multicenter study to evaluate the safety and performance of the
      AltaValve for the treatment of moderate to severe or severe mitral valve regurgitation in
      subjects who are considered high risk for mortality and morbidity from conventional
      open-heart surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2019</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiac Event</measure>
    <time_frame>30 days</time_frame>
    <description>Cardiac death, stroke, mitral valve related repeated intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success</measure>
    <time_frame>30 days</time_frame>
    <description>Technical Success per MVARC criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>30 days</time_frame>
    <description>Device success and absence of major device or procedure related serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>30 days</time_frame>
    <description>Device Success per MVARC criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MR grade</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Mitral Regurgitation</condition>
  <condition>Mitral Insufficiency</condition>
  <condition>Mitral Valve Incompetence</condition>
  <condition>Mitral Valve Regurgitation</condition>
  <condition>Mitral Incompetence</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AltaValve</intervention_name>
    <description>Transcatheter Mitral Valve Replacement</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects ≥ 18 years of age.

          2. Subjects symptomatic New York Heart Association (NYHA) II-IV.

          3. Subjects with severe MR as documented by echo.

          4. Subjects who are at high risk for open-heart surgery as documented by the health care
             professional (e.g., Heart Team consisting of cardiac surgeon and interventional
             cardiologist in United States).

        Abbreviated Exclusion Criteria:

          1. Inability to understand the study or a history of non-compliance with medical advice.

          2. Unwilling or unable to sign the Informed Consent Form (ICF).

          3. History of any cognitive or mental health status that would interfere with study
             participation.

          4. Currently enrolled in any other pre-approval investigational study (does not apply to
             long-term post-market studies unless these studies might clinically interfere with the
             current study endpoints (e.g., limit use of study-required medication, etc.)).

          5. Female subjects who are pregnant or planning to become pregnant within the study
             period.

          6. Known hypersensitivity or contraindication to aspirin, heparin, or Warfarin without
             adequate alternative medications.

          7. Known hypersensitivity to nitinol (i.e., nickel allergy) that cannot be adequately
             medicated.

          8. Known hypersensitivity to contrast media that cannot be adequately medicated.

          9. Evidence of current Left Ventricular Ejection Fraction (LVEF) ≤25% (where current is
             defined as the latest LVEF measurement completed within 90 days prior to the index
             procedure).

         10. Concurrent medical condition with a life expectancy of less than 12 months.

         11. Prior mitral valve repair/replacement (excluding prior surgical mitral valve repair,
             annuloplasty, or MitraClip not interfering with AltaValve placement).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Genereux, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Morristown Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vinayak Bapat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Britney Kotaska</last_name>
    <phone>+1-612-428-7130</phone>
    <email>altavalveEFS@4cmed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erika Youngstrom</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MedStar Washington Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin C Collins, MPH</last_name>
      <phone>202-877-6622</phone>
      <email>erin.c.collins@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Ron Waksman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Shultz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prairie Heart Institute</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62769</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Hudson</last_name>
      <phone>217-492-9100</phone>
      <phone_ext>29151</phone_ext>
      <email>shudson@prairieresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Melissa McHugh, MS</last_name>
      <phone>217-492-9100</phone>
      <phone_ext>29110</phone_ext>
      <email>MMchugh@prairieresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nilesh Goswami, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Christy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CentraCare Hearth and Vascular Center</name>
      <address>
        <city>Saint Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peggy Dahl, RN</last_name>
      <phone>320-251-2700</phone>
      <phone_ext>52187</phone_ext>
      <email>dahlp@centracare.com</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Humbert, BSN</last_name>
      <phone>320-251-2800</phone>
      <phone_ext>57560</phone_ext>
      <email>humbertj@centracare.com</email>
    </contact_backup>
    <investigator>
      <last_name>Thom Dahle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daren Danielson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine VanZile</last_name>
      <phone>201-787-2254</phone>
      <email>catherine.vanzile@atlantichealth.org</email>
    </contact>
    <investigator>
      <last_name>Philippe Genereux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Slater, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atrium Health</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Duncan, RN, MSN</last_name>
      <phone>704-355-4796</phone>
      <email>maria.duncan1@atriumhealth.org</email>
    </contact>
    <investigator>
      <last_name>Michael Rinaldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Skipper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NC Heart &amp; Vascular Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicol Trader</last_name>
      <phone>919-787-5380</phone>
      <phone_ext>1018564</phone_ext>
      <email>caroline.trader@unchealth.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Willis Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Curtis Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Green, RN, BSN</last_name>
      <phone>713-441-3629</phone>
      <email>lmgreen@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Michael Reardon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Neal Kleinman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cyntia Pennestri</last_name>
      <phone>514-376-3330</phone>
      <phone_ext>2236</phone_ext>
      <email>cyntia.pennestri@icm-mhi.org</email>
    </contact>
    <investigator>
      <last_name>Anita Asgar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel Pellerin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Université Laval</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shriley Baril</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>4129</phone_ext>
      <email>shirley.baril@criucpq.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Josep Rodes-Cabau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francois Dagenais, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shonan Kamakura General Hosptial</name>
      <address>
        <city>Kamakura</city>
        <state>Kanagawa</state>
        <zip>247-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 21, 2019</study_first_submitted>
  <study_first_submitted_qc>June 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2019</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mitral Regurgitation</keyword>
  <keyword>TMVR</keyword>
  <keyword>Functional Regurgitation</keyword>
  <keyword>Degenerative Regurgitation</keyword>
  <keyword>Transcathether Mitral Valve Replacement</keyword>
  <keyword>Primary Regurgitation</keyword>
  <keyword>Secondary Regurgitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

